Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22387268 | 1.00 | ATM (0.37) | ATM | |
| SCHEMBL15580903 | 1.00 | ATM (0.37) | ATM | |
| SCHEMBL21651987 | 0.85 | ATM (0.32) | ATM | |
| SCHEMBL24696717 | 0.83 | ATM (0.31) | ATM | |
| SCHEMBL15705743 | 0.77 | ATM (0.37) | ATM | |
| SCHEMBL24090554 | 0.77 | ATM (0.37) | ATM | |
| SCHEMBL22763813 | 0.75 | ATM (0.39) | ATM | |
| SCHEMBL1107789 | 0.75 | ATM (0.39) | ATM | |
| SCHEMBL16487711 | 0.75 | ATM (0.39) | ATM | |
| SCHEMBL680283 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-30 | — | — | US | disclosed |
| US-11708359-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-25 | — | — | US | disclosed |
| US-20230117611-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-20 | — | — | US | disclosed |
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD (CN) | 2020-09-03 | — | — | US | disclosed |
| US-8012961-B2 | Tricyclic antibiotics | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-09-06 | — | — | US | disclosed |
| US-8012961-B2 | Tricyclic antibiotics | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-09-06 | — | — | US | disclosed |
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708359-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, LIPC | ATM 3668/4885 |
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | IDO1, HDAC1, HDAC2 | ATM 1715/4885 |
| US-20230117611-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | LIPC, LPL, MGLL | ATM 2371/4885 |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LIPC | ATM 3668/4885 |
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | OPRM1, UBE2D3, METTL3 | ATM 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.